SCHEMBL6490106

SCHEMBL6490106

CCOC(=O)Nc1ccc(Cn2c(C)nc3ccc(C(=O)OC)nc32)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
MAPT P10636 6/20 0.47
KDM4E B2RXH2 5/20 0.47
HPGD P15428 4/20 0.47
HTT P42858 4/20 0.47
HSD17B10 Q99714 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
DGAT1 O75907 1/20 0.43
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
GAA P10253 1/20 0.40
NPC1 O15118 5/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
AGPAT2 O15120 1/20 0.40
RAB9A P51151 4/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489907 0.92 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6491394 0.92 ALDH1A1 (0.49) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6300368 0.90 SMN1; SMN2 (0.50) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6502802 0.89 SMN1; SMN2 (0.43) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6503682 0.89 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6299423 0.88 ALDH1A1 (0.52) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6494739 0.87 MAPT (0.51) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6299695 0.87 MAPT (0.51) ALDH1A1MAPTKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL6493155 0.87 MAPT (0.43) ALDH1A1MAPTKDM4EHPGDHTT
SCHEMBL6499790 0.86 ALDH1A1 (0.49) ALDH1A1MAPTKDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A ALDH1A1 476/4885MAPT 4144/4885KDM4E 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.